A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1
NCT00306631
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
65
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
MKC-1
Sponsor
CASI pharmaceuticals, Inc.